OneMedNet Corporation (NASDAQ: ONMD), a Minneapolis-based provider of real-world data for life sciences, medical devices, and AI developers, has approved a 1-for-10 reverse stock split to comply with Nasdaq’s minimum bid price listing requirements. The move, effective at 12:01 a.m. Eastern Time on Monday, September 29, 2026, follows stockholder approval at the company’s annual meeting on September 18, 2026, with the final split ratio determined by the board of directors within the approved range.
Under the split, each ten shares outstanding will be consolidated into one share, reducing the total from approximately 59.3 million shares to about 5.93 million shares. The authorized share count remains unchanged. The stock will trade under the existing ticker symbol ONMD with a new CUSIP number of 68270C202. No fractional shares will be issued; any remaining fractions will be rounded up to whole shares.
The split is intended to address Nasdaq’s minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market. It will proportionally adjust equity incentive plans, including restricted stock units, warrants, and other equity instruments, without altering their underlying value or par value.
Continental Stock Transfer & Trust Company will serve as the exchange and transfer agent, with no action required from electronic shareholders to receive post-split shares.
OneMedNet’s platform supports data-driven decision-making for clients in life sciences, medical devices, and AI, maintaining its focus on real-world evidence and innovation in healthcare technology.
